BACKGROUND Myocardial H 2 receptor activation may promote cardiac fibrosis and apoptosis in pre-clinical models
H istamine H 2 receptor antagonists (H2RAs) are commonly used to treat gastroesophageal reflux disease (1) and have a relatively strong safety profile. Beyond their use for symptomatic control of gastroesophageal reflux, H2RAs also may have a role in cardiac disease. Similar to beta receptors, H 2 receptors activate stimulatory G-proteins in the myocardium (2, 3) . Blockade of histamine receptors or histamine release can prevent heart failure (HF) in rabbits exposed to doxorubicin and dogs with pacemaker-driven tachycardia (4) (5) (6) . Relative to mice with an intact H 2 receptor, mice with the H 2 receptor knockout had improved cardiac function and developed less fibrosis when subjected to aortic banding (7) . H 2 receptor activation may increase mitochondrial permeability in cardiac myocytes and myocardial susceptibility to stress (8) .
In men and women with HF and reduced ejection Cardiac magnetic resonance imaging (CMR) was obtained at the baseline examination for the majority of MESA participants. In a subset of these participants, CMR was repeated approximately 10 years later (12) . The CMR protocol and interpretation of LV parameters in the MESA study have been previously described and are included in the Online Appendix (13, 14) .
MEDICATION USE. A validated medication inventory was used to assess medication use (10, 15) . Participants were asked to bring all medications used during the 2 weeks before a The mean age of the study sample was 62.3 years, 52.7% were women, and 37.9% were white. The 313 H2RA users in the cohort evaluated for incident HF tended to be older and heavier, were more likely to be white and to use other non-H2RA medications, and had a higher prevalence of hypertension than 6,065 nonusers ( Table 1) Table 2) . Associations were similar with adjustment for co-medication use, when the cohort was restricted to propensity-matched participants, and when the cohort was restricted to participants who used either H2RAs or proton pump inhibitors ( Table 2 ).
The largest unadjusted risk difference for HF was seen in participants with the highest predicted risk Tables 1 and 2 for adjusted and unadjusted associations incorporating time varying definitions of H2RA exposure).
H2RA use was associated with differences in baseline CMR. After adjustment for covariates, H2RA (A) Unadjusted Kaplan-Meier cumulative event curve for incident heart failure (HF) in all participants, (B) locally weighted scatterplot smoothing (LOWESS) comparing incident heart failure occurring at any point during follow-up relative to the baseline predicted risk of heart failure (predicted by the ARIC heart failure score), (C) unadjusted Kaplan-Meier cumulative event curve for incident heart failure in participants at LOW risk for heart failure (predicted by an ARIC heart failure score #11), and (D) unadjusted Kaplan-Meier cumulative event curve for incident heart failure in participants at high risk for heart failure (predicted by an ARIC heart failure score >11). ARIC ¼ Atherosclerosis Risk in Communities; H2RA ¼ H 2 receptor antagonist.
Leary et al. Table 4 ). Increasing consistency of H2RA use over time suggested progressively stronger associations with change over time in LVEDV, LV stroke volume, and mass/volume ratio ( Table 3) . (17, 18) . These findings join previous observations in animal models to suggest a biologically plausible, histamine-related mechanism important to the pathogenesis of HF (4, 6, 7) . This is the first report to suggest H2RA use is associated with decreased HF incidence in humans, but not the first to suggest H2RA use may be important for the heart. Among 318 Japanese participants with HFrEF, use of famotidine (an H2RA) was associated with better New York Heart Association functional class, lower BNP, and a smaller LVEDV (9) . In a subsequent prospective randomized trial of 50 participants with HF, Kim et al. Improved HF symptoms may be related, but are distinct from our description of decreased HF incidence, and our study suggested important differences relative to these previous studies. Among participants with HFrEF, randomized famotidine use was associated with a smaller LV diameter. This agrees with our current cross-sectional observation of a smaller 
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